BC
VSTM icon

Birchview Capital’s Verastem VSTM Stock Holding History

Birchview Capital’s Portfolio VSTM Stock Details VSTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$795K Hold
150,000
– – 0.45% 47
2025
Q4 		$1.16M Buy
+150,000
New +$1.34M 0.68% 36

Other funds holding VSTM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Birchview Capital's VSTM Position: Q1 2026 in Review

Birchview Capital held its Verastem (VSTM) position steady in Q1 2026 at 150,000 shares worth $795K. The position accounts for 0.45% of the portfolio, ranked #47.

Birchview Capital first reported a position in VSTM in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.16M in Q4 2025. 155 funds tracked by Wall St. Rank hold VSTM as of Q1 2026.

  • Birchview Capital held 150,000 shares of Verastem worth $795K as of Q1 2026.
  • Birchview Capital left its Verastem share count unchanged in Q1 2026.
  • Verastem made up 0.45% of Birchview Capital's portfolio in Q1 2026, its #47 holding.
  • Birchview Capital first reported a position in Verastem in Q4 2025 and has held it in 2 quarters since.
  • Birchview Capital's Verastem position peaked at $1.16M in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Verastem as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.